Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Steroid plus mycophenolate mofetil for double high-risk primary membranous nephropathy
ChiCTR2600125299Phase 4Recruiting
- Sponsor
- Huashan Hospital
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mycophenolate mofetil in idiopathic membranous glomerulonephritis (IMG), sponsored by Huashan Hospital. Primary endpoint: overall remission rate. Started May 2026; status: recruiting.
02
Drugs
mycophenolate mofetil
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on ChiCTR2600125299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125299.